Seres Therapeutics (NASDAQ:MCRB) Stock Passes Below 50 Day Moving Average – Time to Sell?

Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $16.63 and traded as low as $14.50. Seres Therapeutics shares last traded at $15.05, with a volume of 38,823 shares trading hands.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Seres Therapeutics in a report on Monday, December 29th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Reduce” and an average price target of $14.33.

Seres Therapeutics Price Performance

The stock has a 50 day moving average price of $16.63 and a 200-day moving average price of $16.72. The stock has a market capitalization of $136.20 million, a price-to-earnings ratio of -4.22 and a beta of 0.22.

Institutional Investors Weigh In On Seres Therapeutics

A number of large investors have recently modified their holdings of the business. Bank of America Corp DE raised its position in shares of Seres Therapeutics by 2,772.6% in the third quarter. Bank of America Corp DE now owns 5,343 shares of the biotechnology company’s stock valued at $103,000 after buying an additional 5,157 shares during the last quarter. Schonfeld Strategic Advisors LLC purchased a new stake in Seres Therapeutics during the 3rd quarter valued at about $557,000. Vanguard Group Inc. raised its holdings in Seres Therapeutics by 6.8% in the 3rd quarter. Vanguard Group Inc. now owns 311,889 shares of the biotechnology company’s stock valued at $6,001,000 after acquiring an additional 19,793 shares during the last quarter. Vontobel Holding Ltd. lifted its stake in Seres Therapeutics by 22.6% in the 3rd quarter. Vontobel Holding Ltd. now owns 98,511 shares of the biotechnology company’s stock worth $1,895,000 after purchasing an additional 18,186 shares in the last quarter. Finally, Marshall Wace LLP purchased a new position in Seres Therapeutics in the 2nd quarter worth approximately $1,016,000. Hedge funds and other institutional investors own 59.34% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.